![]() ![]() ![]() We look forward to having more involvement in the NCODA community.” Prior to this process, we had already adopted patient-centered practices however, we are constantly striving for enhancements and this accreditation allows us just that. At Rx To Go, we do a tremendous job supporting our patients and our team. ![]() “The emphasis on medical integration, and its importance in the oncology care model, has been very constructive for everyone involved. ![]() “Participating in the NCODA MIP Accreditation has been a valuable opportunity for our team and patients,” said Kara Sammons, Director of Quality and Compliance – Pharmacy for Rx To Go. The newly accredited practices include Clearview Cancer Institute, Rx To Go, LLC at Florida Cancer Specialists & Research Institute, and Southern Oncology and Hematology Associates. Subjects who have an active, known or suspected autoimmune disease.– Three leading medically integrated oncology practices were awarded NCODA’s Center of Excellence Medically Integrated Pharmacy Accreditation at the NCODA International Spring Forum that took place on March 15 – 17, 2023 in Indianapolis, IN. Requires treatment with strong CYP3A inhibitors known bleeding disorders or Major surgery within 4 weeks of first dose of study drug History of stroke or intracranial hemorrhage within 6 months prior to enrollment Concomitant use of warfarin or other Vitamin K antagonists Cetuximab or panitumumab (CRC cohort 4) Any taxane ( UC cohort of ibrutinib + paclitaxel) (cohort 2) Everolimus or temsirolimus (RCC cohort 1) Estimated Creatinine Clearance ≥30 mL/min (Cockcroft-Gault) docetaxel is administered, these subjects must have bilirubin within normal origin, such as hemolysis) with the exception of subjects in the GC cohort where Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of Alkaline phosphatase <3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present limit of normal (ULN) if liver metastases, or ≤3 x ULN without liver metastases Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤5.0 x upper Adequate hepatic and renal function defined as: Hemoglobin ≥9.0 g/dL for cohort 4 (CRC) for cohort 1 (RCC),all UC cohorts, and cohort 3 (GC) Platelet counts >100,000 cells/mm3 (100 x 109/L) for all UC cohorts Absolute neutrophil count ≥1500 cells/mm3 (1.5 x 109/L) For CRC: minimum of 2 and maximum of 4 prior regimens, which must have included bothĪn irinotecan and an oxaliplatin based regimen unless unable to tolerate irinotecan Which must have included a fluoropyrimidine regimen For gastric or GEJ adenocarcinoma: minimum of 1 and maximum of 3 prior regimens one of Of neo- or adjuvant therapy with a platinum chemotherapy. Locally advanced or mUC who have progressed on platinum chemo or within 12 months Score (CPS) of ≥ 10 without prior treatment. Locally advanced or mUC who are not eligible for cisplatin chemo with a PDL-1 For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have For UC cohort 2: minimum of 1 and maximum of 2 prior regimens, one of which must have For RCC: minimum of 1 and maximum of 4 prior regimens, one or more of which must have Gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR RCC (clear cell), urothelial carcinoma (UC) (transitional cell), gastric or Phase 2: To assess the ORR of ibrutinib combination therapy in GC, CRC, UC cohort 6, and ibrutinib as a single agent in UC cohort 5 Phase 2: To assess progression-free survival (PFS) of ibrutinib in combination with everolimus in RCC, and ibrutinib in combination with paclitaxel for UC cohort 2. Phase 1b: To confirm the RP2D of single-agent ibrutinib in UC cohort 5 Phase 1b: To determine the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in UC cohort 2, docetaxel in GC, cetuximab in CRC, and pembrolizumab in UC cohort 6 The purpose of this study is to evaluate the safety, tolerability, and efficacy of singleĪgent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel,ĭocetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary Grants and Research Funding Opportunities. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |